ArchiMed’s $1.2bn private equity deal with Natus Medical was the Medical devices industry’s biggest cross border deal of Q2 2022 as cross border deals worth $6.9bn were announced globally in the quarter, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
The value marked an increase of 1.9% over the previous quarter and a drop of 44.7% when compared with the last four-quarter average of $12.52bn.
In terms of number of cross border deals, the sector saw a drop of 16.28% with 153 deals in Q2 2022 against the average of 182.75 deals in the last four-quarters.
In value terms, Europe led the activity with cross border deals worth $3.5bn.
Medical devices industry cross border deals in Q2 2022: Top deals
The top five Medical devices industry cross border deals accounted for 55.5% of the overall value during Q2 2022.
The combined value of the top five cross border deals stood at $3.84bn, against the overall value of $6.9bn recorded for the quarter.
The top five Medical devices industry cross border deals of Q2 2022 tracked by GlobalData were:
1) ArchiMed $1.2bn private equity deal with Natus Medical
2) The $1bn acquisition of MediFox DAN Group by ResMed
3) EQT IX Fund $797.86m private equity deal with SPT Labtech
4) The $541.63m acquisition of Phenox by Wallaby Medical
5) CVS Health,Export Development Bank of Iran,General Atlantic,Mass Mutual Ventures,Openspace Ventures,Sequoia Capital and SoftBank Vision Fund II $300m venture financing deal with Biofourmis
Verdict deals analysis methodology
This analysis considers only announced and completed cross border deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.